{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:47:56Z","timestamp":1789602476505,"version":"build-2803163510"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Currently, three chimeric antigen receptor (CAR)-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have been approved by the U.S. Food and Drug Administration for the treatment of large B cell lymphoma, which provide a novel and promising choice for patients with relapsed or refractory to traditional anti-tumor treatments. Thus, it is pertinent to describe the efficacy and safety profile of the three products available by summarizing the current evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two reviewers independently searched the Embase, PubMed, Web of Science, and Cochrane Library, to identify studies related to the use of the three CAR-T cell products for treating hematologic malignancies published up to October 5, 2020. We pooled the overall response rate, complete response rate, cytokine release syndrome, and immune effector cell-associated neurotoxicity syndrome of three products, and then performed subgroup analysis based on the type of product and type of tumor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-three studies involving 2,172 patients were included in the analysis. All three products showed promising results in patients with different pathological subtypes and clinical characteristics that included those who did not meet the eligibility criteria of licensing trials, with overall response rates of nearly 70% or above and complete response rates of more than 50%. However, high rates of severe immune effector cell-associated neurotoxicity syndrome in patients undergoing axicabtagene ciloleucel treatment and life-threatening cytokine release syndrome in patients with leukemia undergoing tisagenlecleucel treatment required special attention in practice (31%; 95% CI: 0.27\u20130.35 and 55%; 95% CI: 0.45\u20130.64, respectively). Moreover, lisocabtagene maraleucel that showed a favorable efficacy and safety in the licensing trial lacked corresponding real-world data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both axicabtagene ciloleucel and tisagenlecleucel showed considerable efficacy in practice, but need special attention with respect to life-threatening toxicity that can occur in certain situations. Lisocabtagene maraleucel demonstrated\u00a0excellent efficacy and safety profiles in the licensing\u00a0trial, but lacked corresponding real-world data. Additional data on the three products are needed in rare histological subtypes to benefit a broader patient population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.698607","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T13:31:16Z","timestamp":1627306276000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Jun","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoQin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RenDe","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengSi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JianChao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T Cell Immunotherapy for Human Cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric Antigen Receptor T-Cell Therapy-Assessment and Management of Toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric Antigen Receptor (CAR) T Therapies for the Treatment of Hematologic Malignancies: Clinical Perspective and Significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The Fourth Generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating Anti-CD19 CAR T-Cell Therapy Into Clinical Practice for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"132","author":"Chow","year":"2018","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/cancers11010047","article-title":"Chimeric Antigen Receptor T-Cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review With Meta-Analysis","volume":"11","author":"Yu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01056-8","article-title":"Individual Patient Data Meta-Analysis From 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients With Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia","volume":"36","author":"Li","year":"2019","journal-title":"Adv Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3425291","DOI":"10.1155\/2019\/3425291","article-title":"Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis Markers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus Med Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13380","article-title":"B Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma: A Meta-Analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S203822","article-title":"Survival Outcomes and Efficacy of Autologous CD19 Chimeric Antigen Receptor-T Cell Therapy in the Patient With Diagnosed Hematological Malignancies: A Systematic Review and Meta-Analysis","volume":"15","author":"Drokow","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.04.005","article-title":"The Efficacy of Anti-CD19 Chimeric Antigen Receptor T Cells for B-Cell Malignancies","volume":"21","author":"Cao","year":"2019","journal-title":"Cytotherapy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017506","article-title":"Efficiency and Safety of Autologous Chimeric Antigen Receptor T-Cells Therapy Used for Patients With Lymphoma: A Systematic Review and Meta-Analysis","volume":"98","author":"Cao","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30277-5","article-title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphocytic Leukaemia: A Systematic Review and Meta-Analysis","volume":"7","author":"Anagnostou","year":"2020","journal-title":"Lancet Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1786563","article-title":"Patient Selection for Chimeric Antigen Receptor (CAR) T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas","volume":"61","author":"Johnson","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn204","article-title":"Commentary: Heterogeneity in Meta-Analysis Should be Expected and Appropriately Quantified","volume":"37","author":"Higgins","year":"2008","journal-title":"Int J Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in Patients With DLBCL Treated With Commercial CAR T Cells Compared With Alternate Therapies","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection During the First Year in Patients Treated With CD19 CAR T Cells for Diffuse Large B Cell Lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.025","article-title":"Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"26","author":"Schubert","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging Therapy Prior to Axicabtagene Ciloleucel for Relapsed\/Refractory Large B-Cell Lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-Of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and Feasibility of Chimeric Antigen Receptor T Cell Therapy After Allogeneic Hematopoietic Cell Transplantation in Relapsed\/Refractory B Cell Non-Hodgkin Lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene Ciloleucel CD19 CAR-T Cell Therapy Results in High Rates of Systemic and Neurologic Remissions in Ten Patients With Refractory Large B Cell Lymphoma Including Two With HIV and Viral Hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.127684","article-title":"Anti-CD19 CAR T Cells With High-Dose Melphalan and Autologous Stem Cell Transplantation for Refractory Multiple Myeloma","volume":"4","author":"Garfall","year":"2019","journal-title":"JCI Insight"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J\u00a0Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-Cell Therapy in Secondary CNS Lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B37","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.10.003","article-title":"Early Positron Emission Tomography\/Computed Tomography as a Predictor of Response After CTL019 Chimeric Antigen Receptor \u2013T-Cell Therapy in B-Cell Non-Hodgkin Lymphomas","volume":"20","author":"Shah","year":"2018","journal-title":"Cytotherapy"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.12.018","article-title":"Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells After Treatment With Axicabtagene Ciloleucel","volume":"16","author":"Fehse","year":"2020","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/cells9051225","article-title":"Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients With Relapsed\/Refractory NHL or ALL","volume":"9","author":"Korell","year":"2020","journal-title":"Cells"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25951","article-title":"Commercial Anti-CD19 CAR T Cell Therapy for Patients With Relapsed\/Refractory Aggressive B Cell Lymphoma in a European Center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune Effector Cell\u2013Associated Neurotoxicity Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes","volume":"23","author":"Holtzman","year":"2020","journal-title":"Neuro Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and Radiologic Correlates of Neurotoxicity After Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-1434","article-title":"Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients With Large B-Cell Lymphoma Treated With Axicabtagene Ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical Activity of Axicabtagene Ciloleucel in Adult Patients With Richter Syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of Anti-CD19 CAR T Cell Infusion Products Associated With Efficacy and Toxicity in Patients With Large B Cell Lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High Metabolic Tumor Volume Is Associated With Decreased Efficacy of Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"key":"B51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy","volume":"2114","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719841581","article-title":"CAR T-Cell Therapy for B-Cell Lymphomas: Clinical Trial Results of Available Products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-Cell Toxicity Grading Systems: Application of the ASTCT Grading System and Implications for Management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of Cytokine Release Syndrome Associated With the CAR T Cell Therapy Tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity After Adoptive Immunotherapy With CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16638","article-title":"Real-World Data of High-Grade Lymphoma Patients Treated With CD19 CAR-T in the UK","volume":"189","author":"Kuhnl","year":"2020","journal-title":"Br J Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01120-w","article-title":"Axicabtagene Ciloleucel CD19 CAR T-Cells for Relapsed\/Refractory Large B-Cell Lymphoma: Realworld Outcomes, Toxicity and Predictors of Response From a Prospective UK Cohort","volume":"55","author":"Sanderson","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3881","article-title":"Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-ITOC7.95","article-title":"CD19 CAR T-Cells for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data From LMU Munich","volume":"8","author":"B\u00fccklein","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000404","article-title":"Real-World Results of Anti-CD19 CAR T Cells Use for Patients With Relapsed\/Refractory Large B-Cell Lymphoma in Lyon Sud Hospital","volume":"4","author":"Sesques","year":"2020","journal-title":"HemaSphere"}],"updated-by":[{"DOI":"10.3389\/fonc.2021.768128","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.698607\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T01:20:09Z","timestamp":1633828809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.698607\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":62,"alternative-id":["10.3389\/fonc.2021.698607"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.698607","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fonc.2021.768128","asserted-by":"object"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"article-number":"698607"}}